Plazomicin: A Next‐Generation Aminoglycoside
- 4 December 2018
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 39 (1), 77-93
- https://doi.org/10.1002/phar.2203
Abstract
Plazomicin is a novel aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit, thus inhibiting protein synthesis via a concentration‐dependent manner. Plazomicin displays a broad spectrum of activity against aerobic gram‐negative bacteria, including extended‐spectrum β‐lactamase–producing Enterobacteriaceae, carbapenem‐resistant Enterobacteriaceae, and organisms with aminoglycoside‐modifying enzymes. In a large phase III clinical trial, plazomicin was shown to be noninferior to meropenem in the treatment of complicated urinary tract infections (cUTI) with respect to the coprimary efficacy endpoints of the microbiologically modified intent‐to‐treat composite cure rate at day 5 (plazomicin 88% [n=168/191] vs meropenem 91.4% [n=180/197]) and at the test‐of‐cure visit (plazomicin 81.7% [n= 156/191] vs meropenem 70.1% [n= 138/197]). In a small phase III clinical trial, plazomicin was shown to be effective in the treatment of infections caused by carbapenem‐resistant Enterobacteriaceae and was associated with a lower all‐cause mortality or significant disease‐related complication rate (23.5% [n=4/17]) compared with colistin (50% [n=10/20]). The most common adverse reactions associated with plazomicin are decreased renal function, diarrhea, hypertension, headache, nausea, vomiting, and hypotension. As with other aminoglycosides, plazomicin may cause neuromuscular blockade, otoxicity, and fetal harm in pregnant females. Due to limited efficacy and safety data, plazomicin is indicated for the treatment of cUTI in adults with limited or no alternative treatment options, using a dosage regimen of 15 mg/kg intravenously every 24 hours for 4–7 days. Dosage reductions and therapeutic drug monitoring are warranted in patients with moderate or severe renal impairment. Plazomicin is not recommended in patients with severe renal impairment, including those receiving renal replacement therapy. With the approval of plazomicin, clinicians now have an additional option for the treatment of adults with cUTIs, particularly those caused by multidrug‐resistant gram‐negative rods.Keywords
This publication has 37 references indexed in Scilit:
- Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?American Journal of Infection Control, 2018
- A Systematic Review of the Burden of Multidrug-Resistant Healthcare-Associated Infections Among Intensive Care Unit Patients in Southeast Asia: The Rise of Multidrug-ResistantAcinetobacter baumanniiInfection Control & Hospital Epidemiology, 2018
- Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolatesJournal of Antimicrobial Chemotherapy, 2017
- Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired InfectionsAntimicrobial Agents and Chemotherapy, 2017
- Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and ManagementPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012Antimicrobial Agents and Chemotherapy, 2014
- Trends in Aminoglycoside Use and Gentamicin-Resistant Gram-Negative Clinical Isolates in US Academic Medical Centers: Implications for Antimicrobial StewardshipInfection Control & Hospital Epidemiology, 2012
- Optimizing Aminoglycoside UseCritical Care Clinics, 2011
- Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York CityJournal of Antimicrobial Chemotherapy, 2010
- Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic-Resistant Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2010